Identification of a Functional ceRNA Network to Explore Potential Biomarkers for Hepatocellular Carcinoma

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Zhijun Jiang^{1,*}
Yu Zhang^{1,*}
Xinyu Liu¹
Jingchen Liang²
Guanhua Qiu²
Xiaoqi Zhu²
Jie Chen¹
Lequn Li¹

¹Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, People's Republic of China; ²Department of Ultrasound, Guangxi Medical University Cancer Hospital, Nanning, People's Republic of China

*These authors contributed equally to this work

Purpose: To establish a novel circRNA-miRNA-mRNA network associated with the poor prognosis of hepatocellular carcinoma (HCC).

Materials and Methods: Quantitative real-time PCR was used to verify the differentially expressed circRNA. Moreover, the competing endogenous RNA networks were established using bioinformatics methods. Meanwhile, the prognostic value and potential mechanism of ceRNA network in hepatocellular carcinoma (HCC) were analyzed.

Results: This work found that *circ_0130911* was highly expressed in HCC tissues and early recurring HCC. Further, we effectively constructed a ceRNA network. The ceRNA network regulated by *circ_0130911* might influence the prognosis of HCC by regulating cell cycle-related pathways.

Conclusion: The ceRNA network proposed here can be used as a novel biomarker for the prognosis of HCC, thereby providing new insights for the targeted therapy of HCC.

Keywords: circRNAs, ceRNAs, biomarker, hepatocellular carcinoma

Introduction

Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors with its incidence and mortality rates ranking 6th and 4th respectively across the globe.^{1,2} Due to the current limitation of medical technology, HCC patients in the Asia-Pacific region are primarily treated via radical resection.³ Nonetheless, after radical resection of HCC, nearly 70% of patients still develop recurrence of HCC. As a consequence, the overall treatment level of HCC and the improvement of the survival rate of HCC patients remain severely affected.² Therefore, it is necessary to identify the risk factors and potential mechanisms related to the early recurrence of HCC after radical resection geared towards providing novel treatment approaches for controlling the early recurrence and metastasis of HCC.

Circular RNAs (circRNAs) are a type of single-stranded endogenous non-coding RNA (ncRNA) with a covalently closed-loop structure. The ncRNA on the other hand is produced by reverse splicing and exhibits a circular structure that cannot be easily degraded by RNA exonuclease. Therefore, it has a more stable structure compared to linear RNA.^{4,5} Notably, circRNAs are widely distributed in cells and have tissue-specific expressive characteristics. At the same time, circRNAs might participate in miRNAs sponge, epithelial-mesenchymal transition, and tumorigenesis.⁶⁻⁹ Thus, the dysregulation of circRNAs expression might influence the development of cancer. For instance,

Correspondence: Lequn Li; Jie Chen
Department of Hepatobiliary Surgery,
Guangxi Medical University Cancer
Hospital, Nanning, People's Republic of
China
Tel +86 771 533 0855
Fax +86 771 531 2000
Email lilequn82@163.com;
jiechen185@163.com

circSHKBP1 (*hsa_circ_0000936*) regulates the *HUR-VEGF* pathway to inhibit *HSP90* degradation by sponging *miR-582-3p*, thereby promoting the progression of gastric cancer.¹⁰ Also, recent studies have shown that *circ0003998* regulates the expression of *FOSL2* and *PCBP1-CD44v6* through sponge *miR-143-3p* to participate in the process of epithelial-mesenchymal transition of HCC.¹¹ Moreover, *circPTK2* (*hsa_circ_0005273*) is highly expressed in colorectal cancer and positively correlated with tumor growth and metastasis. Based on various studies, *circPTK2* could promote EMT of colorectal cancer cells by physically binding to the phosphorylation sites *Ser38*, *Ser55*, and *Ser82* of vimentin thereby improving the metastasis of colorectal cancer. Therefore, *circPTK2* has been predicted to become a potential target for the treatment of colorectal cancer metastasis.¹²

In this study, 3 early recurrence and 3 early recurrence-free cases were selected for circRNA high-throughput sequencing in the preliminary work of our group. As a result, *hsa_circ_0130911* was highly expressed in patients with early recurrence of HCC. Through qRT-PCR and bioinformatics, we found that the expression of *circ_0130911* was upregulated in HCC tissues, and positively correlated with tumor growth and metastasis. Besides, the expression of *circ_0130911* was positively correlated with lower mediocre survival rates and poorer tumor-free survival in HCC patients. Additionally, a complete ceRNA network was constructed to predict the potential mechanism of *circ_0130911*. This work thus provides a strong foundation for the study of circRNAs related to the early recurrence of HCC. However, further experiments should be conducted to explore the specific regulatory mechanisms.

Materials and Methods

circRNA High-Throughput Sequencing

We selected 3 early recurrence cases and 3 early recurrence-free HCC tissues for circRNA high-throughput sequencing to detect the expression of circRNA.

Specimen of HCC Tissues

A total of 106 pairs of primary HCC tissues and 106 matched normal liver tissue samples used in this study were provided by the Affiliated Tumor Hospital of Guangxi Medical University. The diagnosis and cut-off values of clinical indicators for primary hepatocellular carcinoma were based on the Chinese guidelines for the diagnosis and treatment of primary HCC.¹³ First, 106 tissues from patients were removed during liver resection, frozen in liquid nitrogen, and stored at -80°C before RNA isolation. After the operation, all patients were followed

up via outpatient review, inpatient review, and telephone follow-up. The follow-up date ended in May 2018. Table 1 records the clinical characteristics of 106 patients. The Ethics Committee of the Affiliated Tumor Hospital of Guangxi Medical University approved the study, and all 106 patients signed the relevant informed consent.

Quantitative Real-Time PCR

The total RNA of 106 pairs of HCC tissues was extracted using TRIzol reagent (Invitrogen, USA). PrimeScript RT reagent Kit with gDNA Eraser kit (Takara, Japan) was used to reverse transcribedTM into cDNA, while FastStart Universal SYBR Green Master (ROX) (Roche, Germany) was used for real-time quantitative polymerase chain reaction (qRT-PCR) analysis. The expression level of circRNA was calculated by the $2^{-\Delta\Delta\text{CT}}$ method (standardized with $\beta\text{-Actin}$). The primers for *circ_0130911* were 5'-CCTTGGAGGCTGAGTGG -3' and 5'-CTTCATCACCTGCTTACTTTC -3'. The primers for $\beta\text{-Actin}$ were 5'- TGC GTGACATTAAGGAGAAG -3' and 5'- GTCAGGCAGCTCGTAGCTCT -3'.

Prediction of circRNA-miRNA-mRNA Interaction Network

Notably, Cancer-Specific CircRNAs Database (CSCD)¹⁴ understands the structural model of *circ_0130911*. The circbank¹⁵ was used to predict the sponge miRNA of *circ_0130911*. Unlike the normal liver tissue samples, the differentially down-regulated miRNAs (DemiRNAs) in HCC were identified by OncomiR and miRCancer. Besides, the intersection of miRNA predicted in circbank and miRNA in OncomiR¹⁶ and miRCancer¹⁷ was considered as the target molecule of *circ_0130911* in HCC. Of note, mRNA was predicted by miRTarBase database.¹⁸ The GEPIA database¹⁹ was used to determine the differentially up-regulated mRNAs in HCC and normal liver tissues. The intersection of mRNA in miRTarBase and GEPIA database was considered as the target gene of *circ_0130911* in HCC. Finally, Cytoscape software 3.7.2 was used to visualize the CircRNA-miRNA-mRNA network.

GO and KEGG Pathway Enrichment Analysis

The clusterProfiler software package in R was used to perform GO annotation and KEGG pathway analysis on the selected mRNA and the most frequently changed neighboring genes.

Table I A Comparison Between *circ_0130911* Expression and Clinicopathological Characteristics in HCC Patients

Characteristic	Total	<i>hsa_circ_0130911</i>		OR (95% CI)	p value
		Low n=53	High n=53		
Gender					
Female	4	3	1	Ref.	0.308
Male	102	50	52	3.120 (0.314–31.002)	
Age (years)					
<65	100	52	48	Ref.	0.093
≥65	6	1	5	5.417(0.611–48.041)	
Tumor diameter					
<5cm	22	9	13	Ref.	0.338
≥5cm	84	44	40	0.629(0.243–1.630)	
Tumor number					
<3	86	44	42	Ref.	0.620
≥3	20	9	11	1.280 (0.482–3.402)	
Child-Pugh					
A	48	28	20	Ref.	0.119
B	58	25	33	1.848(0.852–4.008)	
Portal vein thrombosis					
No	87	48	39	Ref.	0.023
Yes	19	5	14	3.446(1.141–10.406)	
Microvascular invasion					
No	52	28	24	Ref.	0.437
Yes	54	25	29	1.353 (0.631–2.905)	
AFP					
<400	53	37	16	Ref.	<0.001
≥400	53	16	37	5.348 (2.333–12.256)	
Metastasis					
No	90	49	41	Ref.	0.030
Yes	16	4	12	3.585 (1.074–11.966)	
Early recurrence					
No	50	32	18	Ref.	0.006
Yes	56	21	35	2.963 (1.343–6.537)	
BCLC stage					
0+A	59	29	30	Ref.	0.845
B+C	47	24	23	0.926 (0.430–1.994)	

Note: Bold, a significant difference.

Abbreviations: HR, hazard ratio; CI, confidence interval; AFP, α -fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.

Construction and Analysis of Protein-Protein Interaction (PPI) Network and Hub Gene

The PPI networks were established using String database²⁰ and Cytoscape software 3.7.2 visualization. The Hub genes were identified according to the top ten node degree (the number of genes related to the target gene). Oncomine database²¹ and HPA database²²

verified the expression of the selected 10 Hub genes at the transcription and translation levels. The influence of the 10 Hub genes on the prognosis of HCC were verified by the GEPIA database. Using the survivalROC package in R to draw ROC curve and calculate AUC to evaluate the risk value of Hub genes for the prognosis of HCC. Cox $P < 0.05$ was considered to statistically significant.

Gene Set Enrichment Analysis (GSEA)

A total of 10 Hub genes were grouped based on their high and low expressions in the TCGA-LIHC gene set. With the GSEA 4.0.3 software via the Java platform, we derived the “<https://software.broadinstitute.org/gsea/downloads.jsp>” to evaluate the potential biological functions that might be involved. The enriched signaling pathways with $FDR < 0.25$ or nominal $p < 0.05$ were defined as statistically significant.

Statistical Analysis

SPSS 22.0 statistical software was used for all statistical analyses, while GraphPad Prism 8 was used to draw graphs. The chi-square test was used to evaluate the relationship between *circ_0130911* and clinicopathological characteristics. Moreover, the Cox regression model was applied for single factor and multivariate analysis. The Kaplan-Meier method was used to draw OS and DFS curves, and the Log rank test was used to evaluate their statistical significance. With a P value of less than 0.05 ($P < 0.05$), the difference was considered statistically significant. Notably, bioinformatics analysis was mostly performed through

the above-mentioned bioinformatics tools and R language. Genes or miRNAs with $|\log_2(\text{fold change})| > 1$ and $P < 0.05$ were considered statistically significant.

Results

circRNA High-Throughput Sequencing Analysis

In the sequencing results, based on the analysis of the relationship between the expression of the HCC tissues with 3 early recurrence and 3 early recurrence-free, and statistical correlation analysis. We found *circ_0130911* showing a trend of highest expression in HCC tissues with early recurrence ([Supplement Table 1](#)).

Structural Characteristics of *circ_0130911*

The results of the circbase database revealed that *circ_0130911* originated from exons 43 to 50 of the UTRN gene, located at chr6: 144,858,717–144,898,424, and finally formed a mature sequence of 1246 nt in length ([Figure 1](#)). The CSCD database showed that *circ_0130911* comprised the structure of microRNA

Figure 1 The schematic diagram showing the genomic locus of *circ_0130911* in the UTRN gene. Structure patterns of *circ_0130911* based on the CSCD database.

Figure 2 (A) The expression level of *circ_0130911* in HCC tissues is higher than that in corresponding adjacent nontumorous tissues. **(B)** The expression of *circ_0130911* in the HCC tissues of the early recurrence group is higher compared to that in HCC tissues of the early nonrecurrence group (* $p < 0.05$).

response elements (MREs), suggesting that *circ_0130911* potentially regulates key circRNA of HCC development through sponge miRNA.

Up-Regulation of *circ_0130911* in HCC

qRT-PCR technology was used to detect *circ_0130911* in 106 pairs of HCC tissues and corresponding adjacent tissues. Statistical analysis using Mann–Whitney U rank-sum test showed that the relative expression of *circ_0130911* in HCC tissues was significantly higher compared to that in adjacent tissues ($p < 0.05$, Figure 2A); *circ_0130911* was relatively expressed in cancer tissues of patients with early recurrence of HCC. The expression level of *circ_0130911* was significantly higher compared to that of cancer tissues in patients

with early HCC without recurrence ($p < 0.05$, Figure 2B). This suggests that *circ_0130911* might be closely related to the early recurrence of HCC after surgery.

The Relationship Between *circ_0130911* Level in HCC and Clinical Characteristics of Patients

Based on the median relative expression of *circ_0130911* in HCC tissues, HCC patients were subdivided into *circ_0130911* high expression group (53 cases) and low expression group (53 cases). Chi-square test was used to analyze the relationship between *circ_0130911* high expression group and low expression group and clinicopathological characteristics of HCC patients. Consequently, the high expression level of *circ_0130911* was significantly related to

Table 2 Univariate and Multivariate Cox Regression Analyses of Overall Survival

Clinicopathological Parameters	Univariate Analysis			Multivariate Analysis		
	HR	95% CI	<i>p</i>	HR	95% CI	<i>p</i>
Gender	2.705	0.373–19.602	0.325			
Age	0.248	0.034–1.794	0.167			
Tumor diameter	1.577	0.767–3.243	0.216			
Tumor number	2.701	1.473–4.954	0.001	2.632	1.404–4.932	0.003
Child-Pugh	1.408	0.787–2.521	0.249			
Portal vein thrombosis	2.757	1.482–5.131	0.001	1.436	0.715–2.887	0.309
Microvascular invasion	2.426	1.380–4.264	0.002	2.091	1.151–3.798	0.015
AFP level	1.722	0.995–2.979	0.052			
BCLC stage	1.492	0.869–2.560	0.147			
hsa_circ_0130911 expression	2.295	1.314–4.011	0.004	2.254	1.240–4.096	0.008

Note: Bold, a significant difference.

Abbreviations: HR, hazard ratio; CI, confidence interval; AFP, α -fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.

Table 3 Univariate and Multivariate Cox Regression Analyses of Disease-Free Survival

Clinicopathological Parameters	Univariate Analysis			Multivariate Analysis		
	HR	95% CI	p	HR	95% CI	p
Gender	21.88	0.118–4064.671	0.247			
Age	0.928	0.290–2.970	0.899			
Tumor diameter	0.741	0.405–1.358	0.332			
Tumor number	2.183	1.206–3.951	0.01	2.325	1.240–4.359	0.008
Child-Pugh	1.938	1.113–3.374	0.019	1.662	0.929–2.974	0.087
Portal vein thrombosis	1.924	1.050–3.527	0.034	0.837	0.407–1.721	0.629
Microvascular invasion	2.138	1.242–3.680	0.006	1.922	1.070–3.452	0.029
AFP level	1.661	0.978–2.823	0.061			
BCLC stage	1.662	0.982–2.813	0.059			
hsa_circ_0130911 expression	2.260	1.313–3.889	0.003	2.286	1.280–4.080	0.005

Note: Bold, A significant difference.

Abbreviations: HR, hazard ratio; CI, confidence interval; AFP, α -fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.

portal vein tumor thrombus, alpha-fetoprotein, metastasis, and early tumor recurrence (Table 1).

The Relationship Between circ_0130911 Level and Poor Prognosis of HCC Patients

Single-factor and multi-factor COX regression analysis was applied for all the above indicators. The results showed that the high expression of *circ_0130911* was an independent risk factor for death and recurrence of HCC patients. In terms of overall survival rate, the HR of the *circ_0130911* high expression group was 2.295 (95% CI 1.314–4.011, $p=0.008$, Table 2) whereas, in terms of the tumor-free survival rate, the HR of the *circ_0130911* high expression group was 2.260 (95% CI 1.313–3.889, $p=0.005$, Table 3).

Kaplan-Meier statistics showed that the overall survival rate of patients in the *circ_0130911* high expression group ($p=0.002$, Figure 3A) and the tumor-free survival rate of early (within one year) recurrence ($p=0.002$, Figure 3B) were both significantly lower compared to the low expression group. This indicates that the higher the content of *circ_0130911* in HCC tissue, the worse the prognosis of HCC patients, and the higher the possibility of early recurrence.

Prediction and Construction of ceRNA Network

Based on the ceRNA theory, circRNA regulates the up-regulation of related target genes by competitively binding miRNA response elements with miRNA. Therefore, this study established an HCC-related

Figure 3 (A) The high level of *circ_0130911* expression in HCC tissue indicates that the overall survival rate of the patients is worse. (B) The high level of *circ_0130911* expression in HCC tissue indicates that the disease-free survival rate of the patient is worse.

Figure 4 (A) Venn diagram of downregulated DE miRNAs of *circ-0130911*. (B) Venn diagram of upregulated target genes of *circ-0130911*. (C) A circRNA-miRNA-mRNA regulatory network. The network comprises one circRNAs, 7 miRNAs, and 113 genes. CircRNAs, miRNAs, and mRNAs are respectively represented by diamond ovals and rectangles.

Figure 5 Functional enrichment analysis of the ceRNA network. (A) Results of GO analysis, including BP, CC, and MF; (B) Results of KEGG biological process analysis. The horizontal axis represents the gene ratio. The vertical axis represents lots of the GO terms or KEGG pathways. The size and color of a point represent the number and P-value of the pathway, respectively.

ceRNA network through the following steps. First, circRNA-miRNA interaction pairs were predicted in the circbank database, and DE miRNAs that were differentially down-regulated in HCC were screened based on OncomiR and miRCancer databases. After

crossing the 3 data sets, 7 down-regulated DE miRNAs were selected including, *hsa-miR-590-3p*, *hsa-miR-15a-5p*, *hsa-miR-23c*, *hsa-miR-29a-3p*, *hsa-miR-424-5p*, *hsa-miR-497-5p*, and *hsa-miR-592* (Figure 4A). Then, 1442 target genes of 7

DEmiRNAs were predicted through the miRTarBase database. Based on the GEPIA database, this study selected 1481 genes that were differentially and highly expressed in HCC. After the intersection, 113 highly expressed DEmRNAs were screened out (Figure 4B). Finally, based on the DEcircRNA-DEmiRNA pair and DEmiRNA-DEmRNA pair, a circRNA-miRNA-mRNA network was constructed. Cytoscape v3.7.2 was used to visualize the ceRNA network (Figure 4C).

Functional Analysis of mRNAs

To better understand the potential biological functions of *circ_0130911* in the development of HCC, GO (Figure 5A) and KEGG (Figure 5B) pathway enrichment analyses were performed on 113 target genes in the established

ceRNA network. GO biological process (BP) analysis showed that up-regulated target genes were implicated in nuclear division, organelle fission, and mitotic nuclear division. For cellular component (CC) analysis, target genes were significantly enriched in the chromosomal region, focal adhesion, and cell-substrate junction. Additionally, the molecular function (MF) analysis for these DEmRNAs included cadherin binding, cell adhesion molecule binding, and single-stranded DNA binding.

Moreover, the enrichment results of KEGG showed that DEmRNAs exhibit a clear relationship with various cancer-related pathways, such as the *PI3K-Akt* signaling pathway, Cell cycle, Cellular senescence, and *p53* signaling pathway which were closely related to the ceRNA network. The significant GO enrichment terms and KEGG pathways were shown in bubble

Figure 6 (A) PPI network of 113 target genes of *circ_0130911* in HCC. (B) 10 Hub-genes (*CDK1*, *CCNA2*, *CCNB1*, *PPP2R1A*, *CHEK1*, *KIF23*, *BIRC5*, *OIP5*, *RAD51*, *RACGAP1*) in the PPI network. (C) The circRNA-miRNA-Hub-genes axes.

maps using the ggplot2. R package with $P < 0.05$. The results revealed that the constructed ceRNA network was related to multiple pathways regulating the growth of HCC.

Construction of PPI Network and Hub Gene

The STRING database was used to analyze the relationship between the 113 DE mRNAs in the ceRNA network and constructed a PPI network with 78 and 318 edges on the node. Cytoscape 3.7.2 was used to visualize the PPI network (Figure 6A). The top 10 Hub genes were identified using the cytoHubba plugin, including *CDK1*, *CCNA2*, *CCNB1*, *PPP2R1A*, *CHEK1*, *KIF23*, *BIRC5*, *OIP5*, *RAD51*, *RACGAP1* (Figure 6B). Interestingly, an interactive network was also formed between these Hub genes. Then, Cytoscape was used to built the circRNA-miRNAs-Hubs gene networks (Figure 6C).

Identification of Hub Genes

To further understand the biological functions of these 10 Hub genes in HCC, the Oncomine database was used to detect the expression of the Hub genes in HCC. Results suggested that

the level of Hub genes in HCC tissues was significantly higher compared to that in normal tissues. Moreover, the Human Protein Atlas database showed the difference between the actual expression of *CDK1*, *CCNA2*, *CCNB1*, *PPP2R1A*, *CHEK1*, *KIF23*, *BIRC5*, *OIP5*, *RAD51*, and *RACGAP1* in normal liver tissue and HCC through immunohistochemistry (Figure 7A–J). The patient data of the IHC are listed in Table 4. Subsequently, the GEPIA database was used to evaluate the impact of these Hub genes on the prognosis of HCC. As a result, elevated expressions of *CDK1*, *CCNA2*, *CCNB1*, *PPP2R1A*, *CHEK1*, *KIF23*, *BIRC5*, *OIP5*, *RAD51*, and *RACGAP1* suggested a shorter survival time (Figure 8A–J) and tumor-free survival (Figure 9A–J).

Using the TCGA-LIHC database to incorporate these Hub genes into a single-factor, multi-factor COX risk regression model, *CCNB1*, *OIP5*, and *RACGAP1* showed significant prognostic value for HCC patients. The risk values of these 3 Hub genes were combined to draw the ROC curve, and the AUC value was calculated as 0.771 (Figure 10A). This indicates that *CCNB1*, *OIP5*, and *RACGAP1* in the established ceRNA network might be potential biomarkers for predicting the prognosis of HCC.

Figure 7 Validating the expression of 10 Hub genes on transcriptional and translational level by the Oncomine database and HPA database (immunohistochemistry). (A) *CDK1*. (B) *CCNA2*. (C) *CCNB1*. (D) *PPP2R1A*. (E) *CHEK1*. (F) *KIF23*. (G) *BIRC5*. (H) *OIP5*. (I) *RAD51*. (J) *RACGAP1*.

Table 4 Clinical Information of IHC in the Human Protein Atlas Database

Gene Symbol	Tissue Type	ID	Age	Gender	Staining
<i>CDK1</i>	Liver	1899	29	Female	Not detected
<i>CDK1</i>	Carcinoma hepatocellular	2325	76	Male	Medium
<i>CCNA2</i>	Liver	2251	50	Female	Not detected
<i>CCNA2</i>	Carcinoma hepatocellular	5177	60	Female	Medium
<i>CCNB1</i>	Liver	1720	67	Male	Not detected
<i>CCNB1</i>	Carcinoma hepatocellular	929	49	Male	Medium
<i>KIF23</i>	Liver	3378	73	Male	High
<i>KIF23</i>	Carcinoma hepatocellular	2177	58	Female	High
<i>BIRC5</i>	Liver	1846	32	Female	Low
<i>BIRC5</i>	Carcinoma hepatocellular	2325	76	Male	Medium
<i>OIP5</i>	Liver	3402	54	Female	Not detected
<i>OIP5</i>	Carcinoma hepatocellular	5034	76	Male	Medium
<i>RAD51</i>	Liver	3402	54	Female	Low
<i>RAD51</i>	Carcinoma hepatocellular	983	53	Female	High
<i>RACGAP1</i>	Liver	3402	54	Female	Not detected
<i>RACGAP1</i>	Carcinoma hepatocellular	3196	65	Male	Medium
<i>PPP2R1A</i>	Liver	3402	54	Female	Low
<i>PPP2R1A</i>	Carcinoma hepatocellular	2766	73	Female	Medium
<i>CHEK1</i>	Liver	1720	67	Male	Not detected
<i>CHEK1</i>	Carcinoma hepatocellular	2556	72	Male	High

GSEA

The TCGA database was used to further determine the possible pathways and mechanisms of these 3 Hub genes in regulating the progress of HCC. Based on their median, the Hub genes were divided into high expression and low expression groups (Figure 10B–D). GSEA was conducted to search for the GO and KEGG pathways enriched in the highly-expressed samples. The results revealed that the high expression of these 3 Hub genes were enriched in the pathways such as “kegg_cell_cycle”, “go_cell_cycle_g1_s_phase_transition” (FDR $q < 0.05$). Therefore, the ceRNA network might promote the development of tumors by regulating the cell cycle and other pathways.

Discussion

Based on the latest data released by the National Cancer Center, hepatocellular carcinoma (HCC) is the 4th leading cancer in China with its 2014 incidence being about 26.67 per 100,000. It causes the cancer-related deaths of approximately 319,000 people annually, with its death rate only second to lung cancer.²³ The existing guidelines recommend that hepatectomy is a vital method to ensure the long-term survival of HCC patients, and significantly improves the prognostic quality of life among patients.²⁴ Nonetheless, the high recurrence rate

and short survival time of HCC patients negatively impact the improvement of the overall treatment level of HCC. Also, this is attributed to its biological characteristics including strong invasiveness, high malignancy, and poor prognosis.

Accumulating evidence has shown that circRNA plays an important role in the progression of HCC. As hypothesized by the ceRNA network, circRNA regulates the expression of mRNA through the sponge miRNA of MREs structure.⁹ As such, circRNA exerts its biological functions through an extensive gene expression regulatory network, and can as well be used as a diagnostic and prognostic biomarker. For instance, Exosomal *circPACRGL* acts as a sponge for *miR-142-3p/miR-506-3p* and promotes progression of colorectal cancer via the *miR-142-3p/miR-506-3p-TGF- β 1* axis. Shang et al established a ceRNA network that might play a role in the early recurrence of HCC, thereby providing new ideas for monitoring the early recurrence of HCC.²⁵

Furthermore, studies conducted by Xu et al have shown that the upregulated expression of *circ-CCAC1* in cholangiocarcinoma increases cell progression by sponging *miR-514a-5p* and up-regulating YY1. Besides, it promotes the occurrence and metastasis of cholangiocarcinoma, and might be an important organism markers for the treatment of cholangiocarcinoma.²⁶

Figure 8 Association of expressions among 10 upregulated Hub genes and the overall survival of patients with HCC. (A) *CDK1*. (B) *CCNA2*. (C) *CCNB1*. (D) *PPP2R1A*. (E) *CHEK1*. (F) *KIF23*. (G) *BIRC5*. (H) *OIP5*. (I) *RAD51*. (J) *RACGAP1*.

Figure 9 Association of expressions among 10 upregulated Hub genes and the disease-free survival of patients with HCC. (A) *CDK1*. (B) *CCNA2*. (C) *CCNB1*. (D) *PPP2R1A*. (E) *CHEK1*. (F) *KIF23*. (G) *BIRC5*. (H) *OIP5*. (I) *RAD51*. (J) *RACGAP1*.

Based on qRT-PCR results, *circ_0130911* was relatively and highly expressed in HCC tissues and was closely related to the poor prognosis of HCC. Importantly, the biological function of *circ_0130911* in tumors is largely understudied. Therefore, our research is of great significance for further understanding the mechanism of circRNA in HCC.

By predicting the miRNAs bound to circRNA, 7 down-regulated DE miRNAs were identified, including: *hsa-miR-590-3p*, *hsa-miR-15a-5p*, *hsa-miR-23c*, *hsa-miR-29a-3p*, *hsa-miR-424-5p*, *hsa-miR-497-5p*, and *hsa-miR-592*. In addition, several lines of evidence have shown that these 7 DE miRNAs are related to the development and metastasis of cancer and that the expression of *miR-590-3p* is

Figure 10 (A) ROC analysis of 3 Hub genes in TCGA-LIHC database. The Enrichment plots from GSEA analysis of Hub genes in the TCGA-LIHC dataset. (B) *CCNB1*. (C) *OIP5*. (D) *RACGAP1*.

downregulated in triple-negative breast cancer. Besides, *miR-590-3p* directly inhibits the invasion and migration ability of triple-negative breast cancer by sponge slugs.²⁷ A research by He et al found that *circZNF609* activates the Hedgehog pathway through the sponge *miR-15a-5p/15b-5p* and promotes the expression of *GLI2* protein, thereby enhancing the proliferation and metastatic capability of HCC cells.²⁸ In bladder cancer, *lncRNA CASC9* acted as a *miR-497-5p* sponge to up-regulate the expression of *FZD6*, activate the *Wnt/β-catenin* signaling pathway, as well as promote the growth and metastasis of bladder cancer.²⁹ Additional studies have revealed that *circFGFR3* participates in the *miR-29a-3p/E2F1* axis by inducing the EMT process of ovarian cancer cells and promote the initiation of ovarian cancer.³⁰

In total, we found 113 DEmRNAs in the established ceRNA network. KEGG pathway enrichment analysis suggests that the up-regulated genes were primarily implicated

in the following pathways: *PI3K-Akt* signaling and cell cycle and *p53* signaling pathways. Reports indicate that changes in cell cycle rhythm are closely related to the occurrence and development of HCC.³¹ The imbalance of the *p53* signaling pathway promotes the proliferation of HCC cells, thereby contributing to the occurrence of HCC.³²

To further determine the key genes in the ceRNA network, we considered the top 10 genes in the PPI network as Hub genes including, *CDK1*, *CCNA2*, *CCNB1*, *PPP2R1A*, *CHEK1*, *KIF23*, *BIRC5*, *OIP5*, *RAD51*, and *RACGAP1*. Then, the circRNA-miRNA-Hub mRNA network was constructed. The Oncomine and HPA databases were used to verify the true expression of Hub genes in HCC at the transcription and translation levels. The results indicated that the mRNA levels and immunohistochemical staining of these genes in HCC tissues were significantly higher compared to those in normal tissues, suggesting that these Hub genes regulate the development of HCC. To identify the

potential prognostic markers in HCC, the GEPIA database was used to analyze the OS and DFS of Hub genes in the prognosis of HCC. We found that the high expression of Hub genes was significantly related to the poor prognosis of HCC patients. Moreover, as demonstrated by the results of the COX regression model, the 3 genes (*CCNB1*, *OIP5*, and *RACGAP1*) were the most significant genes influencing the prognosis of HCC. The ROC curve of these 3 Hub genes was used to analyze the relationship with the prognosis of HCC, and the AUC value was calculated as 0.771. Therefore, these 3 Hub genes were predicted as the potential biomarkers for the prognosis of HCC.

We used the TCGA database to perform GSEA enrichment analysis and discovered that when these 10 Hub genes were overexpressed in HCC, they were primarily enriched in Cell cycle, Regulation of gene expression epigenetic, Gene silencing, Cell cycle g1 s phase transition, etc. Reports have confirmed that the dysregulation of cell cycle pathways regulates tumor development and prognosis. For example, *TRIM59* regulates the cell cycle by degrading protein phosphatase 1B, thereby promoting the development of HCC.³³ Based on various sources of evidence, the high expression of *p38 MAPKγ* acts as a CDK-like kinase, which can act synergistically with CDK in regulating cell cycle and promotes the occurrence of liver tumors.³⁴ Also, it has been widely reported that the Hub gene discovered in this work can affect tumor development through the cell cycle pathway. Notably, *CCNB1* was found to be highly expressed in HCC. *LINC00346* regulates the expression of *CCNB1* through sponge *miR-199a-3p*, which influences the *p53* signaling pathway and ultimately regulates the cell cycle process of HCC cells.³⁵ He et al found that *OIP5* was up-regulated in patients with glioblastoma, and its expression was positively correlated with the poor prognosis of patients. Further studies highlighted that *OIP5* promotes cell cycle progression, and knocking down *OIP5* will trigger G2/M cell cycle arrest.³⁶ *RACGAP1* is highly expressed in HCC, gastric cancer, and other cancers.^{37,38} For instance, knocking down *RACGAP1* in basal-like breast cancer inhibits the growth of cancer cells through the failure of cytokinesis.³⁹

Here, we propose a novel circRNA-miRNA-mRNA network related to the poor prognosis of HCC. This network might promote the progress of HCC through cell cycle and other pathways, hence it is expected to become a novel biomarker for predicting the poor prognosis of HCC. Nevertheless, our findings primarily relied on qRT-

PCR and bioinformatics predictions. Thus, additional experiments are necessary to validate our hypothesis.

Conclusion

In conclusion, this work used qRT-PCR to validate that the expression level of *circ_0130911* in HCC tissues is significantly different from that in adjacent tissues. As a consequence, we effectively established a complete circRNA-miRNA- Hub genes network by the analysis of bioinformatics research strategies of multiple databases. Moreover, it was found that the *CCNB1*, *OIP5*, and *RACGAP1* in the network might influence the poor prognosis of HCC patients by regulating the cell cycle and other pathways. Eventually, we uncovered that *circ_0130911* acts as a ceRNA in regulating the cell cycle geared towards promoting the progress of HCC and providing novel biomarkers for the prognosis of HCC. Nevertheless, the specific mechanism by which this ceRNA network regulates the development of HCC merits further research.

Abbreviations

BP, biological process; CC, cellular component; CI, confidential interval; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; HCC, hepatocellular carcinoma; PPI, protein-protein interaction network; qRT-PCR, quantitative real time PCR; GSEA, Gene Set Enrichment Analysis.

Ethics and Consent Statement

This research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Subjects have given their written informed consent and the study protocol regarding human specimen were approved by the Ethics Committee of the Affiliated Tumor Hospital of Guangxi Medical University.

Funding

This study was supported by grants from the National Natural Science Foundation of China (grant number 81960534 and 81860512) and the Innovation Driven Development Project of Guangxi (AA18221001).

Disclosure

The authors declare that they have no conflicts of interest in this work.

References

1. Fitzmaurice C, Allen C, Barber RM, et al.; Global Burden of Disease Cancer C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer Groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. *JAMA Oncol.* 2017;3(4):524–548. doi:10.1001/jamaoncol.2016.5688
2. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nat Rev Gastroenterol Hepatol.* 2019;16(10):589–604.
3. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int.* 2017;11(4):317–370.
4. Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet.* 2019;20(11):675–691. doi:10.1038/s41576-019-0158-7
5. Meng S, Zhou H, Feng Z, et al. CircRNA: functions and properties of a novel potential biomarker for cancer. *Mol Cancer.* 2017;16(1):94. doi:10.1186/s12943-017-0663-2
6. Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in cancer. *Cell.* 2019;176(4):869–81 e13. doi:10.1016/j.cell.2018.12.021
7. Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs. *Cell.* 2015;160(6):1125–1134. doi:10.1016/j.cell.2015.02.014
8. Zhao Z-J, Shen J. Circular RNA participates in the carcinogenesis and the malignant behavior of cancer. *RNA Biol.* 2017;14(5):514–521. doi:10.1080/15476286.2015.1122162
9. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. *Nature.* 2013;495(7441):384–388. doi:10.1038/nature11993
10. Xie M, Yu T, Jing X, et al. Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation. *Mol Cancer.* 2020;19(1):112. doi:10.1186/s12943-020-01208-3
11. Song LN, Qiao GL, Yu J, et al. Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1. *J Exp Clin Cancer Res.* 2020;39(1):114. doi:10.1186/s13046-020-01576-0
12. Yang HB, Li XB, Meng QT, et al. CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer. *Mol Cancer.* 2020;19(1). doi:10.1186/s12943-020-1139-3
13. Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary HCC in China (2017 edition). *HCC.* 2018;7(3):235–260.
14. Xia SY, Feng J, Chen K, et al. CSCD: a database for cancer-specific circular RNAs. *Nucleic Acids Res.* 2018;46(D1):D925–D929. doi:10.1093/nar/gkx863
15. Glazar P, Papavasiliou P, Rajewsky N. circBase: a database for circular RNAs. *Rna.* 2014;20(11):1666–1670. doi:10.1261/rna.043687.113
16. Wong NW, Chen YH, Chen S, et al. OncomiR: an online resource for exploring pan-cancer microRNA dysregulation. *Bioinformatics.* 2018;34(4):713–715. doi:10.1093/bioinformatics/btx627
17. Xie B, Ding Q, Han H, et al. miRCancer: a microRNA-cancer association database constructed by text mining on literature. *Bioinformatics.* 2013;29(5):638–644. doi:10.1093/bioinformatics/btt014
18. Chou CH, Shrestha S, Yang CD, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. *Nucleic Acids Res.* 2018;46(D1):D296–D302. doi:10.1093/nar/gkx1067
19. Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
20. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
21. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia.* 2007;9(2):166–180. doi:10.1593/neo.07112
22. Thul PJ, Akesson L, Wiking M, et al. A subcellular map of the human proteome. *Science.* 2017;356(6340):6340. doi:10.1126/science.aal3321
23. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin.* 2016;66(2):115–132.
24. Department of Medical Administration N H, Health Commission of the People's Republic of C. Guidelines for diagnosis and treatment of primary HCC in China (2019 edition). *Zhonghua Gan Zang Bing Za Zhi.* 2020;28(2):112–128.
25. Shang A, Gu C, Wang W, et al. Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-beta1 axis. *Mol Cancer.* 2020;19(1):117. doi:10.1186/s12943-020-01235-0
26. Xu Y, Leng K, Yao Y, et al. A novel circular RNA, circ-CCAC1, contributes to CCA progression, induces angiogenesis, and disrupts vascular endothelial barriers. *Hepatology.* 2020. doi:10.1002/hep.31493
27. Yan M, Ye L, Feng X, et al. MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug. *Am J Cancer Res.* 2020;10(3):965–974.
28. He YK, Huang H, Jin L, et al. CircZNF609 enhances hepatocellular carcinoma cell proliferation, metastasis, and stemness by activating the Hedgehog pathway through the regulation of miR-15a-5p/15b-5p and GLI2 expressions. *Cell Death Dis.* 2020;11(5):1–12.
29. Zhan Y, Zhang L, Yu S, et al. Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/ β -catenin signaling pathway in bladder cancer. *J Exp Clin Cancer Res.* 2020;39(1):136. doi:10.1186/s13046-020-01624-9
30. Zhou J, Dong ZN, Qiu BQ, et al. CircRNA FGFR3 induces epithelial-mesenchymal transition of ovarian cancer by regulating miR-29a-3p/E2F1 axis. *Aging (Albany NY).* 2020;12(14):14080–14091. doi:10.18632/aging.103388
31. Liu S, Yang TB, Nan YL, et al. Genetic variants of cell cycle pathway genes predict disease-free survival of hepatocellular carcinoma. *Cancer Med.* 2017;6(7):1512–1522. doi:10.1002/cam4.1067
32. Liu WL, Li XX, Chu ESH, et al. Paired box gene 5 is a novel tumor suppressor involved in the pathogenesis of hepatocellular carcinoma through interaction with p53 signaling pathway. *Gastroenterology.* 2011;140(5):S145. doi:10.1016/S0016-5085(11)60589-1
33. Ying H, Ji L, Xu Z, et al. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B. *Cancer Lett.* 2020;473:13–24.
34. Tomas-Loba A, Manieri E, Gonzalez-Teran B, et al. p38gamma is essential for cell cycle progression and liver tumorigenesis. *Nature.* 2019;568(7753):557–560. doi:10.1038/s41586-019-1112-8
35. Jin JL, Xu HQ, Li WY, et al. LINC00346 acts as a competing endogenous RNA regulating development of hepatocellular carcinoma via modulating CDK1/CCNB1 axis. *Front Bioeng Biotech.* 2020;8. doi:10.3389/fbioe.2020.00054
36. He J, Zhao YZ, Zhao EH, et al. Cancer-testis specific gene OIP5: a downstream gene of E2F1 that promotes tumorigenesis and metastasis in glioblastoma by stabilizing E2F1 signaling. *Neuro-Oncology.* 2018;20(9):1173–1184. doi:10.1093/neuonc/noy037
37. Wang SM, Ooi LLPJ, Hui KM. Upregulation of rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. *Clin Cancer Res.* 2011;17(18):6040–6051. doi:10.1158/1078-0432.CCR-11-0557
38. Saigusa S, Tanaka K, Mohri Y, et al. Clinical significance of RacGAP1 expression at the invasive front of gastric cancer. *Gastric Cancer.* 2015;18(1):84–92. doi:10.1007/s10120-014-0355-1
39. Lawson CD, Fan C, Mitin N, et al. Rho GTPase transcriptome analysis reveals oncogenic roles for rho GTPase-activating proteins in basal-like breast cancers. *Cancer Res.* 2016;76(13):3826–3837. doi:10.1158/0008-5472.CAN-15-2923

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>